Similar Items: Identification of an Immune Cell Gene Signature for Predicting Response and Prognosis in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy
- Correction to “Macro Habitat‐Based T2‐Weighted MRI Radiomics and Deep Learning Fusion for Predicting Treatment Response and Prognosis After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer”
- MRI‐based qualitative, quantitative, and radiomics/deep learning methods for assessing treatment response after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
- Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data
- Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer
- Neoadjuvant versus adjuvant chemoradiotherapy for resectable cT3‐4a esophageal squamous cell carcinoma: A matched cohort analysis
- Fluorescent Multiplex Immunohistochemistry (mIHC) Analyses of Local Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy Revealed the Status of Tumor‐Infiltrating Immune Cells and Predicted the Clinical Outcome